Urologie (Heidelberg, Germany) · 2025
[Radionuclide therapy in 2025: nuclear medicine options in the treatment of metastatic castration-resistant prostate cancer].
Аннотация на английскомСтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Willner Luisa, Tauber Robert, Eiber Matthias
Аннотация
BACKGROUND: Radionuclide therapy continues to gain in importance thanks to promising clinical results. It is a suitable treatment option for many patients and is increasingly establishing itself as a key pillar in the treatment of metastatic castration-resistant prostate cancer (mCRPC).
OBJECTIVE: This article summarizes the current role of radionuclide therapies in the treatment of mCRPC and provides insights into recent developments.
METHODS: Presentation of key study results, current approval labels and ongoing clinical trials.
RESULTS: Significant prolongation of survival through treatment with lutetium-177-PSMA-617 and radium-223-dichloride has led to approval of both substances in late-stage mCRPC. Further study results on the effectiveness of lutetium-PSMA in earlier stages and on the use of the alpha emitter actinium-225 are expected.
OBJECTIVE: This article summarizes the current role of radionuclide therapies in the treatment of mCRPC and provides insights into recent developments.
METHODS: Presentation of key study results, current approval labels and ongoing clinical trials.
RESULTS: Significant prolongation of survival through treatment with lutetium-177-PSMA-617 and radium-223-dichloride has led to approval of both substances in late-stage mCRPC. Further study results on the effectiveness of lutetium-PSMA in earlier stages and on the use of the alpha emitter actinium-225 are expected.